Literature DB >> 28249326

Laboratory Assessment of Direct Oral Anticoagulants.

Jonathan Douxfils1, Robert C Gosselin2.   

Abstract

Oral vitamin K anticoagulation (warfarin, Coumadin, coumarin) has long been used for long-term treatment and prophylaxis in a variety of clinical settings. Given the unpredictable pharmacokinetic and food impact of warfarin, episodic monitoring is required. Since the early 2000s, direct oral anticoagulants (DOACs) entered into clinical trials as a potential alternative strategy to oral vitamin K antagonists for long-term anticoagulation. As these drugs have predictable pharmacokinetics and pharmacodynamics, there was no requirement for episodic or routine monitoring. However, shortly after their introduction into clinical use, it became apparent that certain emergent or acute situations may require some capacity to measure these drugs, especially in a bleeding patient with DOAC exposure. The scramble for literature and data to support or suggest laboratory methods which can rapidly and accurately quantify or estimate DOAC concentration soon began. This review describes the literature to date, and recommendations for laboratories to provide tests that will assure either the presence/absence of DOAC or the capacity to quantify DOAC using rapid methods that could be implemented on most clinical laboratory instruments. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28249326     DOI: 10.1055/s-0036-1597296

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  11 in total

1.  Importance of measuring pharmacologically active metabolites of edoxaban: development and validation of an ultra-high-performance liquid chromatography coupled with a tandem mass spectrometry method.

Authors:  Romain Siriez; Lütfiye Alpan; Kossay Elasaad; Philippe Devel; Julie Laloy; Jean-Michel Dogné; Jonathan Douxfils
Journal:  J Thromb Thrombolysis       Date:  2020-04       Impact factor: 2.300

2.  Testing direct oral anticoagulants: embedding in structured long-term care.

Authors:  Hugo Ten Cate
Journal:  Blood Transfus       Date:  2017-10-22       Impact factor: 3.443

3.  Variation in Plasma Levels of Apixaban and Rivaroxaban in Clinical Routine Treatment of Venous Thromboembolism.

Authors:  Sara Reda; Eva Rudde; Jens Müller; Nasim Shahidi Hamedani; Johannes Oldenburg; Bernd Pötzsch; Heiko Rühl
Journal:  Life (Basel)       Date:  2022-05-08

4.  Determination of the cut-off prothrombin time to estimate plasma rivaroxaban overdose status.

Authors:  Bohyun Kim; Seongsoo Jang; Yu-Jin Lee; Nuree Park; Young-Uk Cho; Chan-Jeoung Park
Journal:  J Thromb Thrombolysis       Date:  2020-02       Impact factor: 2.300

5.  Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation.

Authors:  Oliver Königsbrügge; Günter Weigel; Peter Quehenberger; Ingrid Pabinger; Cihan Ay
Journal:  Clin Exp Med       Date:  2018-02-07       Impact factor: 3.984

6.  Pulmonary embolism in patients with COVID-19 pneumonia on adequate oral anticoagulation.

Authors:  Giuseppe Di Tano; Meghi Dede; Irene Pellicelli; Enrico Martinelli; Luigi Moschini; Elva Calvaruso; Gian Battista Danzi
Journal:  J Thromb Thrombolysis       Date:  2021-10-27       Impact factor: 5.221

7.  The value and limitations of new oral anticoagulant plasma level assessments.

Authors:  Lorenz Van der Linden; Julie Hias; Thomas Vanassche
Journal:  Eur Heart J Suppl       Date:  2022-02-14       Impact factor: 1.803

8.  The impact of direct oral anticoagulants in traumatic brain injury patients greater than 60-years-old.

Authors:  Oliver Prexl; Martin Bruckbauer; Wolfgang Voelckel; Oliver Grottke; Martin Ponschab; Marc Maegele; Herbert Schöchl
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2018-03-27       Impact factor: 2.953

Review 9.  Pharmacological reversal of the direct oral anticoagulants-A comprehensive review of the literature.

Authors:  Joseph R Shaw; Deborah M Siegal
Journal:  Res Pract Thromb Haemost       Date:  2018-03-26

10.  Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study.

Authors:  Anne-Laure Sennesael; Anne-Sophie Larock; Jonathan Douxfils; Laure Elens; Gabriel Stillemans; Martin Wiesen; Max Taubert; Jean-Michel Dogné; Anne Spinewine; François Mullier
Journal:  Thromb J       Date:  2018-11-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.